Diffuse Large B-Cell Lymphoma Prognosis (R-IPI)

Determine prognosis in diffuse large B-cell lymphoma

The global unit selector only affects unanswered questions
1.Age?
2.Performance?
3.LDH?
4.Extranodal Sites?
5.Stage?
Created by

1. Age?

Created by
0/5 completed

About this Calculator

The original International Prognostic Index (IPI) was developed and validated prior to the addition of rituximab to curative anthracycline-based chemotherapy. Clinical trials have confirmed that rituximab improves the survival of individuals with diffuse large B-cell lymphoma.

The revised International Prognostic Index (R-IPI) was developed to predict the outcome of individuals receiving rituximab with chemotherapy. The score is able to differentiate patients into three groups (very good, good, poor), all of who have survival >50% in the new era.

References

The original IPI was developed by Shipp et al.

A predictive model for aggressive non-Hodgkin's lymphoma.

New England Journal of Medicine 1993 September 30, 329 (14): 987-94

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.